The detection of Her2 (Neu) in a subgroup of patients with EMPD could provide a new starting point for immunotherapy in a manner similar to therapy for Her2 (Neu)-positive breast cancer patients[13,14]. The gene discussed is ERBB2; the disease is extramammary Paget disease.